Followers | 16 |
Posts | 1145 |
Boards Moderated | 0 |
Alias Born | 03/12/2010 |
Thursday, March 30, 2017 1:27:19 PM
TORONTO, March 30, 2017 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, released today management's review of the first quarter of 2017, which included a review of Q1 accomplishments, a status update on ongoing programs, and its outlook for near term value creation.
Key highlights of the quarterly update include:
•Numerous studies underway and on track to further validate that ProMIS is building a 'best in class' portfolio of therapies targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer's;
•Results announced in January for lead product PMN310 showed prevention of short term memory loss in a well-validated mouse model. ProMIS's other four monoclonal antibodies (mAbs) are undergoing evaluation in the same model, with results expected over the coming months;
•PMN310 on track for IND submission (clinical trial initiation) in late 2018;
•Cohort study underway, evaluating presence and prevalence of ProMIS mAb targets in cerebrospinal fluid (CSF) and blood from Alzheimer's patients, with initial readout expected in the coming months;
•Diagnostics development underway and on track; goal is to create diagnostics to detect different toxic oligomer strains of Amyloid beta in both CSF and blood;
•Discovery programs for TDP43 and Tau, two highly valued targets in neurodegenerative disease and dementia, on track with confirmation of targets and patent submissions expected soon.
"2017 is shaping up to be a very important year for ProMIS, and the year is off to a great start. All our programs are progressing well, and external events continue to support our scientific strategy", said Eugene Williams, Executive Chairman.
"Recently announced results of major clinical trials with competitor products in Alzheimer's strongly support ProMIS' differentiation", stated ProMIS President and CEO, Dr. Elliot Goldstein. "We remain very confident that our mAb programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta will lead to 'best in class therapy' and significant value creation".
Recent PMN News
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences • GlobeNewswire Inc. • 09/12/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/09/2024 08:10:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/09/2024 08:05:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:07 AM
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference • GlobeNewswire Inc. • 07/30/2024 12:30:00 PM
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial • GlobeNewswire Inc. • 07/26/2024 12:35:00 PM
- ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing • GlobeNewswire Inc. • 07/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:25:22 PM
- ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- ProMIS Neurosciences Issues Letter to Shareholders • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- ProMIS Neurosciences, Inc. Announces Leadership Transition • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- ProMIS Neurosciences Announces Publication on Novel Target for ALS • GlobeNewswire Inc. • 12/20/2023 12:00:00 PM
- ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease • GlobeNewswire Inc. • 11/20/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM